Literature DB >> 27055869

Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells.

K Hayakawa1, A M Formica1, M J Colombo1, S A Shinton1, J Brill-Dashoff1, H C Morse Iii2, Y-S Li1, R R Hardy1.   

Abstract

A common feature of B-cell chronic lymphocytic leukemia (CLL) is chromosomal loss of 13q14, containing the miR15a/16-1 locus controlling B-cell proliferation. However, CLL etiology remains unclear. CLL is an adult leukemia with an incidence that increases with advancing age. A unique feature of CLL is biased B-cell antigen receptor (BCR) usage, autoreactivity with polyreactivity and CD5 expression, all suggest a role for the BCR in driving CLL pathogenesis. Among human CLLs, BCRs autoreactive with non-muscle myosin IIA (AMyIIA) are recurrent. Here we identify an unmutated AMyIIA BCR in mouse, with distinctive CDR3 segments capable of promoting leukemogenesis. B cells with this AMyIIA BCR are generated by BCR-dependent signaling during B-1 fetal/neonatal development with CD5 induction, but not in adults. These early-generated AMyIIA B-1 B cells self-renew, increase during aging and can progress to become monoclonal B-cell lymphocytosis, followed by aggressive CLL in aged mice, often with the loss of a chromosomal region containing the miR15a/16-1 locus of varying length, as in human CLL. Thus, the ability to generate this defined autoreactive BCR by B-1 B cells is a key predisposing step in mice, promoting progression to chronic leukemia.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27055869      PMCID: PMC4979312          DOI: 10.1038/leu.2016.61

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  60 in total

1.  The variable genes and gene families of the mouse immunoglobulin kappa locus.

Authors:  R Thiebe; K F Schäble; A Bensch; J Brensing-Küppers; V Heim; T Kirschbaum; H Mitlöhner; M Ohnrich; S Pourrajabi; F Röschenthaler; J Schwendinger; D Wichelhaus; I Zocher; H G Zachau
Journal:  Eur J Immunol       Date:  1999-07       Impact factor: 5.532

2.  A developmental switch in B lymphopoiesis.

Authors:  R R Hardy; K Hayakawa
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

3.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies.

Authors:  Anna Lanemo Myhrinder; Eva Hellqvist; Ekaterina Sidorova; Anita Söderberg; Helen Baxendale; Charlotte Dahle; Kerstin Willander; Gerard Tobin; Eva Bäckman; Ola Söderberg; Richard Rosenquist; Sohvi Hörkkö; Anders Rosén
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

4.  Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.

Authors:  Charles C Chu; Rosa Catera; Lu Zhang; Sebastien Didier; Briana M Agagnina; Rajendra N Damle; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

5.  Correlation between the amino acid position of arginine in VH-CDR3 and specificity for native DNA among autoimmune antibodies.

Authors:  M R Krishnan; N T Jou; T N Marion
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

6.  Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis.

Authors:  Fiona Murray; Nikos Darzentas; Anastasia Hadzidimitriou; Gerard Tobin; Myriam Boudjogra; Cristina Scielzo; Nikolaos Laoutaris; Karin Karlsson; Fanny Baran-Marzsak; Athanasios Tsaftaris; Carol Moreno; Achilles Anagnostopoulos; Federico Caligaris-Cappio; Dominique Vaur; Christos Ouzounis; Chrysoula Belessi; Paolo Ghia; Fred Davi; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

7.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

8.  IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria.

Authors:  Kwan-Ki Hwang; Ashley M Trama; Daniel M Kozink; Xi Chen; Kevin Wiehe; Abby J Cooper; Shi-Mao Xia; Minyue Wang; Dawn J Marshall; John Whitesides; Munir Alam; Georgia D Tomaras; Steven L Allen; Kanti R Rai; Jane McKeating; Rosa Catera; Xiao-Jie Yan; Charles C Chu; Garnett Kelsoe; Hua-Xin Liao; Nicholas Chiorazzi; Barton F Haynes
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

9.  Progenitors for Ly-1 B cells are distinct from progenitors for other B cells.

Authors:  K Hayakawa; R R Hardy; L A Herzenberg; L A Herzenberg
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

10.  The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver.

Authors:  Y S Li; K Hayakawa; R R Hardy
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

View more
  16 in total

Review 1.  Hematopoietic stem cell-independent hematopoiesis and the origins of innate-like B lymphocytes.

Authors:  Eliver Ghosn; Momoko Yoshimoto; Hiromitsu Nakauchi; Irving L Weissman; Leonore A Herzenberg
Journal:  Development       Date:  2019-08-01       Impact factor: 6.868

Review 2.  A Hard(y) Look at B-1 Cell Development and Function.

Authors:  Nicole Baumgarth
Journal:  J Immunol       Date:  2017-11-15       Impact factor: 5.422

Review 3.  Control of B-1a cell development by instructive BCR signaling.

Authors:  Taras Kreslavsky; Jason B Wong; Maria Fischer; Jane A Skok; Meinrad Busslinger
Journal:  Curr Opin Immunol       Date:  2018-02-03       Impact factor: 7.486

4.  Early Generated B-1-Derived B Cells Have the Capacity To Progress To Become Mantle Cell Lymphoma-like Neoplasia in Aged Mice.

Authors:  Kyoko Hayakawa; Anthony M Formica; Yuka Nakao; Daiju Ichikawa; Susan A Shinton; Joni Brill-Dashoff; Mitchell R Smith; Herbert C Morse; Richard R Hardy
Journal:  J Immunol       Date:  2018-06-13       Impact factor: 5.422

5.  Early generated B1 B cells with restricted BCRs become chronic lymphocytic leukemia with continued c-Myc and low Bmf expression.

Authors:  Kyoko Hayakawa; Anthony M Formica; Joni Brill-Dashoff; Susan A Shinton; Daiju Ichikawa; Yan Zhou; Herbert C Morse; Richard R Hardy
Journal:  J Exp Med       Date:  2016-11-29       Impact factor: 14.307

6.  Crucial Role of Increased Arid3a at the Pre-B and Immature B Cell Stages for B1a Cell Generation.

Authors:  Kyoko Hayakawa; Yue-Sheng Li; Susan A Shinton; Srinivasa R Bandi; Anthony M Formica; Joni Brill-Dashoff; Richard R Hardy
Journal:  Front Immunol       Date:  2019-03-15       Impact factor: 7.561

Review 7.  Pathophysiology of chronic lymphocytic leukemia and human B1 cell development.

Authors:  Yoshikane Kikushige
Journal:  Int J Hematol       Date:  2019-12-03       Impact factor: 2.319

Review 8.  Role of Bruton's tyrosine kinase in B cells and malignancies.

Authors:  Simar Pal Singh; Floris Dammeijer; Rudi W Hendriks
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

9.  Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency.

Authors:  Simar Pal Singh; Marjolein J W de Bruijn; Mariana P de Almeida; Ruud W J Meijers; Lars Nitschke; Anton W Langerak; Saravanan Y Pillai; Ralph Stadhouders; Rudi W Hendriks
Journal:  Front Immunol       Date:  2018-09-13       Impact factor: 7.561

10.  circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression.

Authors:  Bo Chen; Weidong Wei; Xiaojia Huang; Xinhua Xie; Yanan Kong; Danian Dai; Lu Yang; Jin Wang; Hailin Tang; Xiaoming Xie
Journal:  Theranostics       Date:  2018-07-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.